A clinical trial to study the effect of tramadol hydrochloride and lignocaine in symptomatic irreversible pulpitis.
Phase 3
- Conditions
- Health Condition 1: K040- Pulpitis
- Registration Number
- CTRI/2024/07/070517
- Lead Sponsor
- SRM Dental College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ASA I
Pain severity with HP-VAS (85mm above) in maxillary molars.
Exclusion Criteria
ASA II and above
Patients with allergy, sensitivity or side effects to tramadol or any opioid drugs.
Negative response to electric pulp testing.
Periodontally compromised teeth.
Patients with bleeding disorders.
Calcified root canals, root resorption, open apex or unrestorable teeth.
Patients who consumed analgesics or antibiotics within 24 hours before the treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To comparatively assess the perioperative analgesic efficacy of tramadol hydrochloride as a local anaesthetic agent in maxillary molars with symptomatic irreversible pulpitis using heft-parker visual analogue scale and brief pain inventory assessment tool.Timepoint: Intraoperative and 6, 12, 24 and 48 hr postoperative.
- Secondary Outcome Measures
Name Time Method Perioperative analgesic efficacyTimepoint: 6, 12, 24 & 48 hr postoperative.